Dr Sheetal Ghelani

Dr. Sheetal Ghelani co-leads the Clinton Health Access Initiative (CHAI) Sickle Cell Disease Program, which is a new program aimed at reducing the pediatric morbidity and mortality of SCD in LMIC via market shaping interventions and healthcare system engagement. She is responsible for managing donor engagement and establishing new strategic partnerships for CHAI’s future SCD work. Additionally, she is the Director of Antimicrobial Resistance. Prior to her SCD and AMR roles, Dr. Ghelani managed CHAI’s Global Health Sciences operations and oversaw internal and external collaborations across several CHAI disease areas to support the development of pre-and post-market drug products in resource-constrained markets. Dr. Ghelani previously supported the development and commercialization of CHAI’s pediatric HIV drug portfolio by coordinating engagement with innovator and generic pharmaceutical companies around technology transfer, pilot and pivotal BE studies, regulatory submissions. Additionally, she is a founding member of WHO’s GAP-f consortium, which aims implement pediatric formulation development of several products in HIV, hepatitis C, TB, and anti-bacterials by bridging the gap between innovator and generic development. Dr. Ghelani has significant experience in public/private partnerships, technology transfer, market shaping, communications, fundraising, price negotiation and research. She holds a Ph.D. in Developmental Immunology.